Skip to Main Content

clinical care

  • sam patrick posted an article
    MUSC SJCH only children’s hospital in South Carolina to be ranked see more

    New rankings from U.S. News & World Report’s (USNWR) 2022-23 Best Children’s Hospitals survey place the MUSC Shawn Jenkins Children’s Hospital once again as the only children’s hospital in South Carolina to be ranked. And, the hospital improved one ranking, to #11, in the Southeast region best children’s hospitals survey. The latest rankings are published online and indicate the herculean efforts health care workers provided during the second year of the coronavirus pandemic.

    The highly recognized specialties for MUSC SJCH include the following national rankings: No. 4 for cardiology & heart surgery, No. 30 for nephrology, No. 31 for cancer and No. 41 for gastroenterology & GI surgery. This year, the MUSC Pediatric & Congenital Heart Center received the #1 spot in the nation ranking for outcomes. This phenomenal achievement recognizes that the pediatric and congenital heart center’s expected outcomes are the best in the nation. USNWR issues the annual rankings “to help families with complex and rare conditions find the best medical care for their children,” according to the publication’s website. They’re designed to steer parents and caregivers to the hospitals that are best equipped to treat their children.

    The 16th annual rankings highlight the top 50 U.S. pediatric hospitals in each of 10 specialties: cancer, cardiology & heart surgery, diabetes and endocrinology, gastroenterology and GI surgery, neonatology, nephrology, neurology and neurosurgery, orthopedics, pulmonology and urology.

    “The U.S. News rankings recognize on a national stage that MUSC Children’s Health is a leader in pediatric health care and a safe and compassionate choice for parents seeking care for their child,” said Mark A. Scheurer, M.D., MUSC Children’s Health chief of clinical services.

    This is the 15th consecutive year that the 4th-ranked cardiology & heart surgery program has made the overall Best Children’s Hospitals list. Criteria include the survival rate of patients after complex heart surgeries along with the level of specialized staff, services and technologies and the ability to prevent infections.

    The nephrology program at the MUSC Shawn Jenkins Children’s Hospital ranks No. 30 in the U.S. That means it excels when it comes to the survival rate of children who have had kidney transplants, the management of dialysis and infection prevention and other factors. It maintains its status as the highest-ranked children’s kidney program in South Carolina. The program ranked #3 in the Southeast for overall care and the third best outcomes.

    The GI & GI surgery program is no stranger to the U.S. News rankings, either. For the 15th year in a row, it made the grade, coming in at No. 41, one spot higher than last year. The rankings factor in the survival rate for children who have had liver transplants, the effectiveness of the hospital’s treatment of children who have inflammatory bowel issues and other key measures. Like all of the rankings, the GI rankings also include input from specialists in the field who responded to U.S. News surveys and recommend the hospital for serious cases in GI care. GI & GI Surgery ranked #8 in the Southeast region.

    Finally, the MUSC Shawn Jenkins Children’s Hospital’s cancer program ranks No. 31 on the list of Best Children’s Hospitals for Cancer. That’s a 13-level increase from last year’s ranking and a direct result of the #15 national ranking in outcomes. Cancer ranked #3 in the Southeast for overall care and achieved the best outcomes in the region. These rankings are based in part on the five-year survival rate for children with leukemia-related cancer, bone marrow transplant services, programs for brain tumors and sarcomas and infection prevention.

    A critical criterion measured by USNWR is outcomes. Five of 10 MUSC Shawn Jenkins Children’s Hospital programs placed in the top 50 nationally for the outcomes portion of their respective survey, including:

    Cardiology & Cardiac Surgery                         #1

    Cancer                                                                  #15

    Nephrology                                                         #26

    Pulmonary                                                          #35

    GI / GI Surgery                                                  #37

    For the second year, U.S. News featured regional rankings, and the MUSC Shawn Jenkins Children’s Hospital tied at #11 for the Southeast region, which is one of the most competitive pediatric regions in the country. Four of MUSC’s pediatric specialties ranked in the top 10: cardiology & cardiac surgery #1, cancer #3, nephrology #3, and GI & GI surgery #8.

    Current methodology combines clinical and operational data, results from a reputational survey of board-certified pediatric specialists and supplemental information from resources such as the National Cancer Institute. RTI International collects and analyzes the data for the rankings. The methodology reflects clinical outcomes, such as patient survival, infection rates and complications; the level and quality of hospital resources directly related to patient care, such as staffing, technology and special services; delivery of health care, such as programs that adhere to best practices and prevent infections; and expert opinion among pediatric specialists. This year, scoring also included an increased focus on the subjects of diversity, equity and inclusion efforts; internal and external affiliations of experts; and clinical issues related to the pandemic.

    “Our MUSC Shawn Jenkins Children’s Hospital care team members continue to be recognized for the outstanding care, service and commitment they provide, even in challenging times,” said Patrick J. Cawley, M.D., MUSC Health CEO and executive vice president for Health Affairs, University. “The strength of our specialty outcomes is a testament to the quality of care our team members seek to provide to patients and their families on a daily basis.”

  • sam patrick posted an article
    Kiyatec invited to present at prestigious conference see more

    Kiyatec, a leader in functional precision oncology, announced new clinical evidence of its proprietary ex vivo 3D cell culture technology use in high-grade glioma will be presented at ASCO 2022. As a first-time ASCO presenter and exhibitor, Kiyatec will present its Clinical Services and Drug Development Services capabilities at ASCO’s first-ever Innovation Hub at kiosk #IH01. The ASCO meeting will be held in Chicago June 3-7, 2022.

    In this updated cohort of 42 patients with high grade glioma, 3D Predict™ Glioma prospectively predicted patient response to standard of care temozolomide (TMZ), regardless of MGMT methylation status. In a subgroup analysis of the 23 MGMT unmethylated patients, test-predicted responders had a relative median progression-free survival advantage of 5.9 months versus test-predicted non-responders (p = 0.0018). This data provides additional evidence of 3D Predict™ Glioma predictivity and its potential to provide additional information for glioma patient treatment options including clinical trial enrollment, alternative therapies indicated for use in glioma or combination therapy with TMZ.

    Kiyatec Chief Executive Officer Matthew Gevaert, PhD, said, “This enhanced cohort adds to our body of clinical evidence demonstrating the predictive insights 3D Predict™ Glioma can provide to neuro-oncologists planning treatment for glioblastoma patients. With it, we’ve advanced our mission is to disrupt cancer care by accurately predicting patient-specific response and non-response before treatment begins.”

    High grade gliomas, including glioblastoma, are among the most aggressive brain cancers, with patients exhibiting highly variable treatment responses in both newly diagnosed and recurrent disease. TMZ with radiation therapy is the guideline-directed standard of care in the newly-diagnosed setting, which has remained relatively unchanged for over 15 years despite variable patient responses.

    Kiyatec’s ex vivo KIYA-Predict™ pre-clinical platform and 3D Predict™ clinical assays are leading the functional precision oncology space with published, clinically-correlated evidence to prospectively predict glioma patient therapeutic response prior to initiation of therapy.

    Clinical application of a functional 3D ex vivo test to predict therapeutic response in patients with HGG: A progression-free survival analysis
    Central Nervous System Tumors
    Sunday June 5 8:00 – 11:00am
    Abstract ID 2031

    About Kiyatec

    Kiyatec is a functional precision oncology company that measures the response of each patient’s live cancer cells to inform oncologists’ treatment selection decisions. The company’s Clinical Services offers clinical testing for high-grade glioma, and is developing assays for use in ovarian, breast, non-small cell lung cancers, and rare tumors in its CLIA-certified lab. The company’s Drug Development Services works in partnership with leading biopharmaceutical companies to unlock response dynamics for their pre-clinical investigational drug candidates across the majority of solid tumor types. For more information, visit www.kiyatec.com and connect with us on LinkedIn and Twitter.

  • sam patrick posted an article
    KIYATEC expands team by adding two executives see more

    KIYATEC, the leader in clinically correlated, published functional precision oncology technology today announced two key appointments as the Company builds utilization of clinical 3D Predict™ assays and grows its pharmaceutical services portfolio for KIYA-PREDICT™. KIYATEC is pleased to welcome Bruce Yeager as Vice President Market Access & Reimbursement effective March 21, 2022, and Steven Holshouser, Ph.D., as Director, Business Development, effective March 8, 2022.

    Chief Executive Officer Matt Gevaert, Ph.D., said, “We are pleased to welcome both Bruce and Steven to our growing team of experienced leaders in their respective fields. Bruce’s significant experience and effectiveness in securing and expanding Medicare and private payer reimbursement and coverage will support the commercialization of 3D Predict™ Glioma and Ovarian assays in 2022 and lays the foundation for reimbursement and coverage plans for our non-small cell lung, rare tumor, and breast cancer assays in the future. Steven’s track record in securing pharmaceutical services contracts will expand revenues from our growing portfolio of clients using KIYA-PREDICT™ therapeutic response and 3D cell culture technology applications in their drug development plans.”

    KIYATEC’s clinical and pre-clinical technology platforms, 3D PredictTM and KIYA-PREDICTTM, respectively, are leading the functional precision oncology space with published evidence of predictive response correlated to clinical outcomes. Recently the Company represented its 3D Predict™ Ovarian publications at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer and announced six abstract acceptances to be presented at the American Association for Cancer Research from April 8-13, 2022 in New Orleans.

    About KIYATEC

    KIYATEC is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D cell culture technology platform. The Company offers clinical tests for high-grade glioma and is developing tests for ovarian, breast, non-small cell lung and rare tumors in its CLIA-certified lab. The Company works with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types. For more information, visit www.KIYATEC.com and connect with us on LinkedIn and Twitter.

  • sam patrick posted an article
    Greenville company enters MOU with global player see more

     Xcelerate, Inc. (OTC pink sheets: "XCRT") today announced that it has signed a Definitive Memorandum of Understanding with HS Pharmaceuticals, LLC of Greenville, SC defining the terms under which Xcelerate, Inc. will acquire 100% of the membership interests in HS Pharmaceuticals, LLC as well as a 51% interest in HS Cosmetics, Inc.

    The DMOU calls for the drafting and signing of an Acquisition Agreement with a pre-determined valuation of HS Pharmaceuticals as well as the raising of capital sufficient to progress the development of HS Pharmaceuticals IP and to fulfill the expansion of the current HS Cosmetics marketing plan launched in April of 2021.

    "Since the announcement of a letter of intent with HS Pharmaceuticals in May, the teams at Xcelerate and HS have been working to define the terms that have resulted in this DMOU and were able to agreement with the assistance of our advisors at Network1 Financial who will be working with us going forward in our capital raising efforts" said Michael O'Shea, Xcelerate CEO."

    "Xcelerate remains focused on joining early-stage medical technology companies in a setting of controlled clinical care where these new developments can be trialed, tested and applied," said O'Shea. 

    For more information, please visit www.xcelerate.global.